These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 24989332

  • 21. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
    Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG.
    Clin Cancer Res; 2019 Oct 01; 25(19):5787-5798. PubMed ID: 31263030
    [Abstract] [Full Text] [Related]

  • 22. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.
    Respir Investig; 2014 Mar 01; 52(2):101-6. PubMed ID: 24636265
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT).
    Lancet; 2016 Apr 02; 387(10026):1405-1414. PubMed ID: 26719230
    [Abstract] [Full Text] [Related]

  • 25. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F.
    Lancet Oncol; 2019 Dec 02; 20(12):1702-1709. PubMed ID: 31628016
    [Abstract] [Full Text] [Related]

  • 26. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
    Hayashi H, Okamoto I, Ichikawa Y, Miyazaki M, Yoshioka H, Kunimasa K, Nakagawa K.
    Int J Clin Oncol; 2010 Oct 02; 15(5):497-9. PubMed ID: 20224880
    [Abstract] [Full Text] [Related]

  • 27. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K.
    Clin Lung Cancer; 2018 Sep 02; 19(5):e705-e707. PubMed ID: 29853412
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE, Fahmy ES.
    Clin Transl Oncol; 2013 Nov 02; 15(11):965-8. PubMed ID: 23408040
    [Abstract] [Full Text] [Related]

  • 31. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A.
    Cancer; 2008 Apr 01; 112(7):1555-61. PubMed ID: 18286536
    [Abstract] [Full Text] [Related]

  • 32. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
    Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
    Mol Cancer Ther; 2013 Jan 01; 12(1):48-57. PubMed ID: 23136186
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.
    Jpn J Clin Oncol; 2008 May 01; 38(5):339-46. PubMed ID: 18434338
    [Abstract] [Full Text] [Related]

  • 34. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
    Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.
    J Thorac Oncol; 2006 Jul 01; 1(6):591-601. PubMed ID: 17409924
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.
    Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Morley A, White P, Rahman NM, De Winton E, Clive A, Masani V, Arnold DT, Dangoor A, Guglani S, Jankowska P, Lowndes SA, Harvey JE, Braybrooke JP, Maskell NA.
    Br J Cancer; 2015 Mar 31; 112(7):1175-82. PubMed ID: 25756396
    [Abstract] [Full Text] [Related]

  • 38. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.
    J Thorac Oncol; 2008 Jul 31; 3(7):756-63. PubMed ID: 18594322
    [Abstract] [Full Text] [Related]

  • 39. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
    Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, Hassan R, Pastan I.
    Mol Cancer Ther; 2015 Dec 31; 14(12):2789-96. PubMed ID: 26443804
    [Abstract] [Full Text] [Related]

  • 40. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
    Green J, Dundar Y, Dodd S, Dickson R, Walley T.
    Cochrane Database Syst Rev; 2007 Jan 24; 2007(1):CD005574. PubMed ID: 17253564
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.